Leading the Way in Life Science Technologies

GEN Exclusives

More »

Corporate Profile

More »
Jun 15, 2010 (Vol. 30, No. 12)

Novel Bisphosphonates Platform for Drug Delivery

MBC Pharma's Technology Allows Anticancer Drugs to Penetrate Down to the Bone

  • Boosting Absorption with B6

    A related technology platform at MBC Pharma links vitamin B6 (pyridoxal phosphate) to bisphosphonates to improve their bioavailability. Most oral bisphosphonates taken for osteoporosis readily enter bone cells, but only about 1% of the dose is absorbed from the intestines. Adding B6 greatly enhances absorption, since almost all cells in the body have receptors for the vitamin that transports the bisphosphonate across the intestinal membrane. Once the conjugate is in circulation, the enzymes that metabolize vitamin B6 release the bisphosphonate portion for distribution to the bone. At this time, however, the development of B6 platform has been placed on hold in order to concentrate on developing conjugates for the oncology platform.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »